Effects of Probiotics on Metabolic Syndrome ,Intestinal Microflora and SCFA.

NCT ID: NCT06183801

Last Updated: 2023-12-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

82 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-01

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The improvement effects of GLAC biotech probiotics contains 5 specialized strains on the biochemical analysis and gut microbiota will be verified in the clinical trial through cooperation with the ADPRC. Through this project, the difference and improvement before and after the GLAC biotech probiotics taking will be clinically validated fromseveral aspects, including blood biochemical values, NGS gut microbiota analysis, GAIS and SCFAs levels. Therefore, by this industry- academic cooperation project, the investigators can explore the improvement of human gut microbiota by GLAC biotech probiotics, to understand the essence of clinical benefit, and the investigators expect the accomplishments of this project can help the consumers understand the added value and excellence of the GLAC products, and thus enhance consumer confidence and expand product markets.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In recent years, the issue of gut microbiota and probiotics has been becoming very popular, and more and more gastrointestinal health foods have been developed and commercialized. The impact of gut microbiota on human health has received increasing attention and expectations from the world. Probiotics are one of the most recognized and positive health materials for consumers. Lactobacillus/probiotics, the main raw materials of health foods most frequently purchased by domestic consumers in recent years, have always ranked the first. They have certain improvement effects in terms of gastrointestinal improvement, immune regulation, and blood lipid regulation. There are currently about 30 probiotic manufacturers in Taiwan. Since the regulations do not have any clinical functional requirements for probiotic products, most probiotic products only describe the characteristics, functions and animal experiments of probiotics. There is no actual clinical experimental data to verify the effect of probiotic products on human intestinal flora. The probiotics researched and developed by GLAC Biotechnology company have undergone rigorous in vitro and animal tests, and actively cooperate with domestic and foreign hospitals to conduct human clinical trials to verify the function of the strains.

With the progress of human culture and lifestyle, many diseases of modern civilization have emerged one after another. Most of these diseases are caused by changes of lifestyle or diet, leading to the human body's metabolic imbalances, such as high blood sugar, high cholesterol, hypertension, hyperuricemia, liver dysfunction, and obesity. Gut dysbiosis and diseases associated with aging usually have such phenomenon like increased pathogenic bacteria, decreased probiotics decrease and declined gut microbiota diversity. The gut dysbiosis contributes to the aging gut and aging-related diseases in at least three aspects including production of Lipopolysaccharides (LPS), reduced levels of short chain fatty acids (SCFAs), and inflamm-aging. The next generation sequencing (NGS) technology can provide high throughput, high sensitivity and reliable detection, and then the investigators can understand improving effects of the human gut microbiota. The Aging and Disease Prevention Research Center (ADPRC) of the Fooyin university has a complete and skilled next generation sequencing (NGS) platform and a gut microbiota database included 5000 clinical cases, and thus provide the best clinical verification platform for probiotic products. Based on the common probiotic/pathogenic markers, reported in most of studies, and 4 specific domestic markers found in our study, the investigators have defined the domestic gut aging index score (GAIS) to predict the aging of the gut. The GASI provides an excellent discrimination. In addition, gut microbiota normally affects inflammatory cytokines by generating SCFAs to modulate the immune system against pathogens. The improvement effects of GLAC biotech probiotics contains 5 specialized strains on the biochemical analysis and gut microbiota will be verified in the clinical trial through cooperation with the ADPRC. Through this project, the difference and improvement before and after the GLAC biotech probiotics taking will be clinically validated from several aspects, including blood biochemical values, NGS gut microbiota analysis, GAIS and SCFAs levels. Therefore, by this industry- academic cooperation project, the investigators can explore the improvement of human gut microbiota by GLAC biotech probiotics, to understand the essence of clinical benefit, and the investigators expect the accomplishments of this project can help the consumers understand the added value and excellence of the GLAC products, and thus enhance consumer confidence and expand product markets.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Probiotics Gut microbiota Metabolic imbalances SCFAs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic 1

Subjects take probiotics capsule three times a day before meal.

Group Type EXPERIMENTAL

Probiotics 1

Intervention Type DIETARY_SUPPLEMENT

Subjects take probiotics capsule(Lactobacillus fermentum,TSF331) three times a day before meal.

Probiotic 2

Subjects take probiotics capsule three times a day before meal.

Group Type EXPERIMENTAL

Probiotics 2

Intervention Type DIETARY_SUPPLEMENT

Subjects take probiotics capsule(Lactobacillus reuteri,TSR332) three times a day before meal.

Probiotic 3

Subjects take probiotics capsule three times a day before meal.

Group Type EXPERIMENTAL

Probiotics 3

Intervention Type DIETARY_SUPPLEMENT

Subjects take probiotics capsule(Lactobacillus plantarum,TSP05) three times a day before meal.

Probiotic 4

Subjects take probiotics capsule three times a day before meal.

Group Type EXPERIMENTAL

Probiotics 4

Intervention Type DIETARY_SUPPLEMENT

Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05) three times a day before meal.

Probiotic 5

Subjects take probiotics capsule three times a day before meal.

Group Type EXPERIMENTAL

Probiotics 5

Intervention Type DIETARY_SUPPLEMENT

Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05+Postbiotics PE0401) three times a day before meal.

Placebo 1

Subjects take probiotics capsule three times a day before meal.

Group Type PLACEBO_COMPARATOR

Placebo 1

Intervention Type DIETARY_SUPPLEMENT

Subjects take capsule three times a day before meal.

Probiotic 6

After 1 month wash out,subjects take probiotics capsule three times a day before meal.

Group Type EXPERIMENTAL

Probiotics 6

Intervention Type DIETARY_SUPPLEMENT

After 1 month wash out, subjects take probiotics capsule(Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.

Probiotic 7

After 1 month wash out,subjects take probiotics capsule three times a day before meal.

Group Type EXPERIMENTAL

Probiotics 7

Intervention Type DIETARY_SUPPLEMENT

After 1 month wash out, subjects take probiotics capsule(Lactobacillus rhamnosus, bv-77+Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.

Placebo 2

After 1 month wash out,subjects take probiotics capsule three times a day before meal.

Group Type PLACEBO_COMPARATOR

Placebo 2

Intervention Type DIETARY_SUPPLEMENT

After 1 month wash out, subjects take capsule three times a day before meal.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotics 1

Subjects take probiotics capsule(Lactobacillus fermentum,TSF331) three times a day before meal.

Intervention Type DIETARY_SUPPLEMENT

Probiotics 2

Subjects take probiotics capsule(Lactobacillus reuteri,TSR332) three times a day before meal.

Intervention Type DIETARY_SUPPLEMENT

Probiotics 3

Subjects take probiotics capsule(Lactobacillus plantarum,TSP05) three times a day before meal.

Intervention Type DIETARY_SUPPLEMENT

Probiotics 4

Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05) three times a day before meal.

Intervention Type DIETARY_SUPPLEMENT

Probiotics 5

Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05+Postbiotics PE0401) three times a day before meal.

Intervention Type DIETARY_SUPPLEMENT

Placebo 1

Subjects take capsule three times a day before meal.

Intervention Type DIETARY_SUPPLEMENT

Probiotics 6

After 1 month wash out, subjects take probiotics capsule(Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.

Intervention Type DIETARY_SUPPLEMENT

Probiotics 7

After 1 month wash out, subjects take probiotics capsule(Lactobacillus rhamnosus, bv-77+Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.

Intervention Type DIETARY_SUPPLEMENT

Placebo 2

After 1 month wash out, subjects take capsule three times a day before meal.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject are willing to provide physical examination reports within the past 1 year.
2. The subject are willing to sign informed consent form.

Exclusion Criteria

1. Pregnant women or preparing for pregnancy.
2. The subject were taking antibiotics.
3. One of parents are not Han Chinese or aboriginal.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Glac Biotech Co., Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hsieh-Hsun Ho

R & D director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hsieh-Hsun Ho, Ph. D.

Role: PRINCIPAL_INVESTIGATOR

Study Principal Investigator

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Glac Biotech Co., Ltd.

Tainan City, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

References

Explore related publications, articles, or registry entries linked to this study.

Lin JH, Lin CH, Kuo YW, Liao CA, Chen JF, Tsai SY, Li CM, Hsu YC, Huang YY, Hsia KC, Yeh YT, Ho HH. Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 improved liver function and uric acid management-A pilot study. PLoS One. 2024 Jul 24;19(7):e0307181. doi: 10.1371/journal.pone.0307181. eCollection 2024.

Reference Type DERIVED
PMID: 39046973 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FYH-IRB-110-01-02

Identifier Type: -

Identifier Source: org_study_id